Skip to main content

Selarsdi News

Teva and Alvotech Announce FDA Approval of Interchangeability for Selarsdi (ustekinumab-aekn) with Stelara (ustekinumab)

PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ...

Monthly News Roundup - October 2024

FDA Approves AbbVie’s Vyalev to Treat Advanced Parkinson Disease In October, the US Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa) for the treatment of motor f...

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of Selarsdi (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara (ustekinumab)

REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...

FDA Approves Selarsdi (ustekinumab-aekn), a Biosimilar to Stelara

REYKJAVIK, Iceland & PARSIPPANY, N.J.--(BUSINESS WIRE) April 16, 2024 --Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Crohn's Disease - Acute, Crohn's Disease, Psoriasis, Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Ulcerative Colitis - Active

Selarsdi patient information at Drugs.com